Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

ConditionPancreas Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorNorthwestern University

About this trial

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Eligibility criteria

Qualifiers

Biopsy or cytology proven adenocarcinoma of the pancreas

No clinical evidence of metastatic disease on imaging

Age 18 or older

Receiving chemotherapy for non-metastatic pancreatic cancer

Disqualifiers

Biopsy proven metastatic disease

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Northwestern University

Lead sponsor

Source ClinicalTrials.gov